RxDoctor Payments Data

Rafael Rios Rivera, MD

Rheumatology · Ponce, PRNPI 1366891590

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $2,253 and has fallen 76.4% since, to $531 in 2025.

$3,711in general payments, 2019–2025

Across 70 payments — averaging $53.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$328
  • AstraZeneca$275
  • Johnson & Johnson$240
  • Amgen$146
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$92
  • plus $348 from 8 others

What the payments were for

  • Consulting fees$1,70046%
  • Travel & lodging$311%
  • Food & beverage$1,98053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,711 in reported general payments places this provider in the 60th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$2,854
Medicare patients
17
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab59$408,729
Orencia ClickjectAbatacept52$318,154
RinvoqUpadacitinib43$277,054
Enbrel SureclickEtanercept14$104,092
Actemra ActpenTocilizumab17$80,673
KevzaraSarilumab18$78,018
ProliaDenosumab15$26,572
Amjevita(Cf) AutoinjectorAdalimumab-Atto12$16,815
MethotrexateMethotrexate Sodium335$5,007
Hydroxychloroquine Sulfate137$3,995
Colchicine31$2,015
Prednisone293$1,928
Naproxen37$1,713
Gabapentin223$1,464
Diclofenac Potassium13$1,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,283$277,05443 claims
AmgenProlia$146$26,57215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →